Le Lézard
Classified in: Health, Science and technology
Subject: Event

ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting


ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.

Oral Presentation Details
Title: Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study
Session: Scientific Plenary I: Progress: Therapeutics Innovations
Session Date: Saturday, March 25, 2023
Session Time: 9:00 am to 10:30 am ET

Additional information can be found at www.sgo.org.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOWtm.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.


These press releases may also interest you

at 16:40
Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. Company Fireside Chat Presentation...

at 16:35
Reata Pharmaceuticals, Inc. ("Reata," the "Company," "our," "us," or "we"), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in...

at 16:35
Vistagen , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer,...

at 16:35
Johnson & Johnson will host a conference call for investors at 8:30 a.m. (Eastern Time) on Thursday, July 20th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk, Executive Vice President and Chief...

at 16:35
Legend Biotech Corporation (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today the submission of a supplemental Biologics License...

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, will host a virtual investor event on Wednesday, June 14, 2023 at 8:00 a.m. Eastern Time. Topics to be covered at the event include: Summary of new IMerge Phase 3 data in lower...



News published on and distributed by: